Overview

myDC/pDC in Stage III Melanoma Patients

Status:
Completed

Trial end date:
2021-09-01

Target enrollment:

Participant gender:

Summary

This is an interventional study to test the immunogenicity of combined adjuvant myDC and pDC vaccination versus adjuvant myDC or pDC vaccination alone in stage III melanoma patients.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Radboud University

Treatments:

Vaccines